DOJ Rescheduling Medical Cannabis May Reignite Bank Interest

Why It Matters

By easing tax burdens and lowering perceived regulatory risk, the rescheduling could unlock financing for cannabis firms, accelerating industry growth and mainstream financial integration.

Key Takeaways

• DOJ reclassifies medical cannabis to Schedule III, opening path to full rescheduling
• 280E tax relief could boost cannabis firms' cash flow and margins
• Banks and credit unions expected to increase cannabis‑related lending activity
• New compliance rules likely to add complexity for both lenders and operators
• DEA hearing set for June 29 signals expedited federal review timeline

Pulse Analysis

The Justice Department’s decision to shift medical cannabis from Schedule I to Schedule III reflects a long‑standing push to align federal policy with state‑level legalization. Since 1970, cannabis has been locked behind the most restrictive schedule, barring research and imposing severe tax penalties. By reclassifying FDA‑approved and state‑approved medical products, the administration not only acknowledges the therapeutic legitimacy of cannabinoids but also paves the way for a full Schedule III status, which would bring the substance in line with other controlled medicines such as certain stimulants and opioids. This regulatory shift is a rare bipartisan concession that could reshape the industry’s fiscal landscape.

For cannabis operators, the most immediate benefit is relief from Section 280E of the Internal Revenue Code. Previously, companies dealing in Schedule I or II substances could not deduct ordinary business expenses, inflating effective tax rates to over 70 percent. Moving to Schedule III permits standard deductions, improving cash flow, margins, and, crucially, lending eligibility. Financial technology firms like Green Check and Safe Harbor Financial are already positioning themselves to provide compliance platforms that satisfy FinCEN and Bank Secrecy Act requirements, making it easier for banks to extend credit without exposing themselves to undue risk. The anticipated influx of capital could accelerate product development, M&A activity, and market consolidation.

However, the path forward is not without hurdles. While the rescheduling eases tax pressure, it introduces a new layer of regulatory oversight across multiple agencies, including the DEA, Treasury, and state regulators. Banks will need robust AML and due‑diligence frameworks tailored to cannabis transactions, and fintech solutions must integrate these controls seamlessly. Moreover, the upcoming DEA hearing on June 29 signals that the federal review process is still evolving, with potential rulemaking that could tighten or relax compliance standards. Stakeholders should monitor these developments closely, as the balance between opportunity and regulatory complexity will determine how quickly the cannabis sector can achieve mainstream financial integration.